DailyMed Update Centers on a Common OTC Antacid
DailyMed’s current label for calcium carbonate chewable tablets places a familiar over-the-counter antacid back in view with unusual clarity: a 750 mg extra-strength formulation sold as an oral chewable tablet for relief of heartburn, sour stomach, acid indigestion, and the upset stomach that often accompanies those symptoms. The product sits in the same therapeutic lane as other calcium carbonate antacids, where rapid acid neutralization is the central pharmacologic move. In practical terms, the tablet is meant to work where reflux symptoms begin — in the stomach lumen, not in the bloodstream.
The label identifies the product as a human OTC drug under the antacid category, packaged by Cardinal Health 110, LLC and distributed under the LEADER brand. Each tablet contains 750 mg of calcium carbonate, and the packaging compares the product to Extra Strength Tums. The formulation comes in assorted fruit flavors and is marketed as gluten-free. Those details may look cosmetic at first glance, but they matter at the bedside and in the pharmacy aisle because palatability, chewability, and brand comparability often determine whether a patient reaches for an antacid during an acute episode.
One sentence captures the core of the label: this is a short-acting symptom reliever, not a chronic disease treatment.
Dose Limits Define the Safety Boundary
The most clinically relevant part of the label is not the flavoring or the tablet color. It is the dosing ceiling. Adults and children 12 years of age and over are directed to chew 2 to 4 tablets completely as symptoms occur, and the label warns against swallowing the tablets whole. The maximum is 10 tablets in 24 hours, with a stricter limit of 6 tablets in 24 hours during pregnancy. Maximum dosing should not extend beyond 2 weeks unless a doctor advises and supervises continued use.
Those instructions reflect the pharmacology of calcium carbonate and the reality of self-treatment. Acid suppression from an antacid is immediate but transient, which is why repeated use can become a proxy for unresolved reflux disease, ulcer disease, or another gastrointestinal process that deserves evaluation. Persistent symptoms beyond 2 weeks are a clinical threshold, not a suggestion. Ongoing heartburn can be benign, but it can also signal gastroesophageal reflux disease, peptic ulcer disease, medication irritation, or a less common structural problem that will not improve simply because the patient keeps chewing tablets.
The label also asks patients to consult a doctor or pharmacist before use if they are taking a prescription drug, because antacids may interact with certain prescription medications. Calcium-containing antacids can impair absorption of some oral agents when taken too close together, so timing remains important even for a product that seems simple and routine. In a pharmacy setting, the main hazard is often not toxicity from a single dose but unrecognized overlap with another treatment.
Pregnancy, Interactions, and the Limits of Self-Care
Pregnancy changes the risk calculus. The label explicitly restricts use to no more than 6 tablets in 24 hours for pregnant users, which is a reminder that “over-the-counter” does not mean “without guardrails.” Reflux symptoms are common in pregnancy, but self-directed dose escalation can create avoidable concerns, especially when patients interpret frequent heartburn as a signal to keep increasing antacid intake.
Calcium carbonate has a straightforward mechanism: it neutralizes gastric acid. That mechanism can bring rapid symptom relief, yet it also explains why overuse may not be benign. Repeated calcium exposure can matter in patients with broader medical issues, and the label’s upper limits are designed to keep routine use within a narrow safety band. The product’s directions, warnings, and packaging all point to the same clinical principle: use the smallest effective amount for the shortest practical duration.
What the Label Says About the Formulation
The label specifies 750 mg of calcium carbonate per tablet and notes that each tablet contains 300 mg of calcium. The inactive ingredients include adipic acid, dextrose, flavoring, magnesium stearate, maltodextrin, starch, sucralose, and color additives including D&C Red No. 27 Lake, D&C Yellow No. 10 Lake, FD&C Blue No. 1 Lake, and FD&C Yellow No. 6 Lake. The tablets are round, 16 mm in size, and colored yellow, green, red, or orange with a fruit flavor profile that includes lemon, orange, cherry, and lime. The imprint code is RP102.
These details do more than identify the product. They help distinguish it from other calcium carbonate chewables and reduce dispensing errors in a crowded OTC market where many products claim similar benefits but differ in strength, flavor, and tablet appearance. For a patient with intermittent dyspepsia, visual recognition can be part of adherence. For a pharmacist or clinician, the imprint and strength are the final checks before recommending a self-care regimen.
A tight formulation like this leaves little ambiguity about its intended use.
Why Persistent Symptoms Still Need Clinical Attention
Heartburn, sour stomach, and acid indigestion are common, but they are not diagnoses. They are symptoms. An antacid can blunt discomfort quickly, yet frequent dependence on rescue dosing may indicate an underlying disorder that deserves a fuller history, medication review, and possibly a different treatment strategy. When symptoms persist despite repeated antacid use, the label’s 2-week boundary becomes clinically meaningful because it marks the point at which self-management should give way to evaluation.
That is especially true when a patient is already taking prescription therapy. Interactions with antacids can undermine the effectiveness of other medications, and the label’s warning to ask a doctor or pharmacist before use reflects that risk. In daily practice, the most useful question is often not whether the patient has heartburn, but whether the symptom pattern is new, worsening, associated with alarm features, or recurring despite repeated OTC treatment.
For now, the label keeps the message simple: this extra-strength antacid is intended for short-term relief, with explicit dose limits, a pregnancy-specific cap, and a firm warning not to keep using maximum doses beyond 2 weeks without medical oversight. The current labeling also anchors the product’s identity in a specific NDC package, 70000-0681-1, with 96 chewable tablets per bottle. In an OTC category defined by ease of access, those details are the boundaries that govern safe use.